Abstract
Digital therapeutics (DTx) are innovative evidence-based medical interventions, driven by high-
quality software programs to prevent, manage, or treat diseases of patients. DTx are also defined
as “drugs” where algorithms are the active ingredient instead of a chemical or biological
substance. DTX can be used alone or in combination with other devices or medications.
DTxs are finding application in a variety of areas, including chronic diseases (type II diabetes,
hypertension, obesity, insomnia, Alzheimer’s), and above all addictions (alcohol, smoking, and
drugs). Today there are roughly 35 to 40 products on the market, 8 of which approved by
regulatory agencies. The value of the global DTx market has been estimated at USD 1.8 billion in
2018, and it is expected to reach USD 8.9 billion by 2027.
DTx differ from common wellness apps or medication reminder tools in that they require
“rigorous” clinical evidence. However, their use raises a number of ethical concerns. Aim of the
present work is to provide an overview of the main ethical issues pertaining the assessment of this
emerging technology. The final purpose is to support and facilitate an open and transparent
ethical debate with regard to DTx.
Lingua originale | English |
---|---|
Titolo della pubblicazione ospite | EACME Annual Conference 2022 |
Pagine | N/A |
Stato di pubblicazione | Pubblicato - 2022 |
Evento | EACME Annual Conference 2022 - Varese Durata: 15 set 2022 → 17 set 2022 |
Convegno
Convegno | EACME Annual Conference 2022 |
---|---|
Città | Varese |
Periodo | 15/9/22 → 17/9/22 |
Keywords
- digital therapeutics